Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients - Takeaways - MDSpire

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

  • By

  • Qi Gao

  • Guoxiang Yao

  • Yujiao Sun

  • Xiaoyun Li

  • Zhuo Li

  • Bing Chen

  • June 26, 2026

  • 0 min

Share

  • 1

    Obinutuzumab is a humanized anti-CD20 monoclonal antibody with enhanced B-cell depletion compared to rituximab, showing promise in treating primary membranous nephropathy.

  • 2

    In a study of 94 PMN patients, 95.74% achieved clinical remission after 24 months of obinutuzumab therapy, with 28.72% attaining complete remission.

  • 3

    The Initial therapy group achieved a 100% clinical remission rate, while the Refractory and Remedial therapy groups had rates of 96.88% and 90%, respectively.

  • 4

    All anti-PLA2R antibody-positive patients showed declining antibody levels post-obinutuzumab treatment, with 68.4% achieving complete immunological remission.

  • 5

    Obinutuzumab demonstrated high clinical remission rates and acceptable safety in PMN patients, including those resistant to rituximab and in refractory cases.

Original Source(s)

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

  • by Qi Gao, Guoxiang Yao, Yujiao Sun, Xiaoyun Li, Zhuo Li, Bing Chen

  • June 26, 2026

Related Content

Restoring immune homeostasis in the spinal microenvironment: targeting mechano-inflammation and immunometabolic reprogramming

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis

Is it time for a systematic and objective assessment of knee laxity? The impact of objective knee laxity after TKA on patient-reported outcomes: a comprehensive review